Literature DB >> 24974945

Long-term survival with cyclophosphamide, bortezomib and dexamethasone induction therapy in patients with newly diagnosed multiple myeloma.

Craig B Reeder1, Donna E Reece, Vishal Kukreti, Joseph R Mikhael, Christine Chen, Suzanne Trudel, Kristina Laumann, Harjot Vohra, Rafael Fonseca, P Leif Bergsagel, Jose F Leis, Rodger Tiedemann, A Keith Stewart.   

Abstract

Entities:  

Keywords:  bortezomib; cyclophosphamide; myeloma; survival

Mesh：

Substances：

Year:  2014        PMID： 24974945     DOI： 10.1111/bjh.13004

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  19 in total

1.  Autologous stem cell transplantation in EBV-positive post-renal transplant refractory multiple myeloma: A case report and literature review.

Authors:  Xiaobao Xie; Yan Lin; Yang Cao; Weimin Dong; Wei Wu; Yuandong Zhu; Deliang Liu; Haiqian Li; Qing Li; Weiying Gu
Journal:  Oncol Lett       Date:  2018-03-12       Impact factor: 2.967

2.  Tolerance, Kinetics, and Depth of Response for Subcutaneous Versus Intravenous Administration of Bortezomib Combination in Chinese Patients With Newly Diagnosed Multiple Myeloma.

Authors:  Yan Xu; Shuhui Deng; Xuehan Mao; Gang An; Zengjun Li; Yafei Wang; Mariateresa Fulciniti; Matthew Ho; Jianhong Lin; Weiwei Sui; Wei Liu; Dehui Zou; Shuhua Yi; Wenyang Huang; Hong Liu; Rui Lv; Jian Li; Tingyu Wang; Chenxing Du; Nikhil C Munshi; Lugui Qiu
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2018-03-15

3.  CRISPR Genome-Wide Screening Identifies Dependence on the Proteasome Subunit PSMC6 for Bortezomib Sensitivity in Multiple Myeloma.

Authors:  Chang-Xin Shi; K Martin Kortüm; Yuan Xiao Zhu; Laura A Bruins; Patrick Jedlowski; Patrick G Votruba; Moulun Luo; Robert A Stewart; Jonathan Ahmann; Esteban Braggio; A Keith Stewart
Journal:  Mol Cancer Ther       Date:  2017-09-27       Impact factor: 6.261

4.  CyBorD induction therapy in clinical practice.

Authors:  N Areethamsirikul; E Masih-Khan; C-M Chu; V Jimenez-Zepeda; D E Reece; S Trudel; V Kukreti; R Tiedemann; C Chen
Journal:  Bone Marrow Transplant       Date:  2015-01-19       Impact factor: 5.483

5.  NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016.

Authors:  Kenneth C Anderson; Melissa Alsina; Djordje Atanackovic; J Sybil Biermann; Jason C Chandler; Caitlin Costello; Benjamin Djulbegovic; Henry C Fung; Cristina Gasparetto; Kelly Godby; Craig Hofmeister; Leona Holmberg; Sarah Holstein; Carol Ann Huff; Adetola Kassim; Amrita Y Krishnan; Shaji K Kumar; Michaela Liedtke; Matthew Lunning; Noopur Raje; Frederic J Reu; Seema Singhal; George Somlo; Keith Stockerl-Goldstein; Steven P Treon; Donna Weber; Joachim Yahalom; Dorothy A Shead; Rashmi Kumar
Journal:  J Natl Compr Canc Netw       Date:  2016-04       Impact factor: 11.908

6.  Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma.

Authors:  E K Mai; U Bertsch; J Dürig; C Kunz; M Haenel; I W Blau; M Munder; A Jauch; B Schurich; T Hielscher; M Merz; B Huegle-Doerr; A Seckinger; D Hose; J Hillengass; M S Raab; K Neben; H-W Lindemann; M Zeis; C Gerecke; I G H Schmidt-Wolf; K Weisel; C Scheid; H Salwender; H Goldschmidt
Journal:  Leukemia       Date:  2015-03-19       Impact factor: 11.528

7.  Triplet RVd Induction for Transplant-Eligible Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis.

Authors:  Guangzhong Yang; Chuanying Geng; Yuan Jian; Huixing Zhou; Wenming Chen
Journal:  Adv Ther       Date:  2022-06-30       Impact factor: 4.070

8.  Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology.

Authors:  Kenneth C Anderson; Melissa Alsina; Djordje Atanackovic; J Sybil Biermann; Jason C Chandler; Caitlin Costello; Benjamin Djulbegovic; Henry C Fung; Cristina Gasparetto; Kelly Godby; Craig Hofmeister; Leona Holmberg; Sarah Holstein; Carol Ann Huff; Adetola Kassim; Amrita Y Krishnan; Shaji K Kumar; Michaela Liedtke; Matthew Lunning; Noopur Raje; Seema Singhal; Clayton Smith; George Somlo; Keith Stockerl-Goldstein; Steven P Treon; Donna Weber; Joachim Yahalom; Dorothy A Shead; Rashmi Kumar
Journal:  J Natl Compr Canc Netw       Date:  2015-11       Impact factor: 11.908

9.  Proteasome Subunits Differentially Control Myeloma Cell Viability and Proteasome Inhibitor Sensitivity.

Authors:  Chang-Xin Shi; Yuan Xiao Zhu; Laura A Bruins; Cecilia Bonolo de Campos; William Stewart; Esteban Braggio; A Keith Stewart
Journal:  Mol Cancer Res       Date:  2020-06-19       Impact factor: 5.852

Review 10.  Treatment-related symptom management in patients with multiple myeloma: a review.

Authors:  Kathleen Colson
Journal:  Support Care Cancer       Date:  2015-02-03       Impact factor: 3.359
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.